

AMENDMENTS TO THE CLAIMS

Please amend the claims as follows, without prejudice or disclaimer. This claim listing replaces all prior listings and versions.

1-39. Cancelled

40. (New) An expression vector useful for immunizing a host comprising nucleic acid sequences encoding modified KSA.

41. (New) The expression vector of claim 40 wherein the vector is a plasmid or a viral vector.

42. (New) The expression vector of claim 41 wherein the viral vector is selected from the group consisting of poxvirus, adenovirus, retrovirus, herpesvirus, and adeno-associated virus.

43. (New) The expression vector of claim 42 wherein the viral vector is a poxvirus selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.

44. (New) The expression vector of claim 43 wherein the viral vector is a poxvirus selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).

45. (New) The expression vector of claim 40 further comprising at least one additional tumor associated antigen.

46. (New) The expression vector of claim 45 wherein the tumor associated antigen is selected from the group consisting of carcinoembryonic antigen, a modified carcinoembryonic antigen, or p53.

47. (New) The expression vector of claim 40 further comprising at least one nucleic acid sequence encoding a co-stimulatory component.

48. (New) The expression vector of claim 47 wherein the co-stimulatory component is selected from the group consisting of B7.1, LFA-3 and ICAM-1.

49. (New) A composition comprising an expression vector of claim 40 in a pharmaceutically acceptable carrier.

50. (New) A method for preventing or treating cancer comprising administering to a host a composition of claim 49.

51. (New) An isolated DNA molecule encoding SEQ ID NO.: 15.

52. (New) An expression vector comprising SEQ ID NO.: 4 and p53 as shown in SEQ ID NO.: 2.

53. (New) The expression vector of claim 52 further comprising SEQ ID NO.: 20.

54. (New) The expression vector of claim 52 further comprising at least one nucleic acid sequence encoding a co-stimulatory component.
55. (New) The expression vector of claim 53 further comprising at least one nucleic acid sequence encoding a co-stimulatory component.
56. (New) The expression vector of claim 54 wherein the co-stimulatory component is selected from the group consisting of B7.1, LFA-3 and ICAM-1.
57. (New) The expression vector of claim 55 wherein the co-stimulatory component is selected from the group consisting of B7.1, LFA-3 and ICAM-1.
58. (New) A method for preventing or treating cancer comprising administering to a host an expression vector of claim 52.
59. (New) A method for preventing or treating cancer comprising administering to a host an expression vector of claim 53.